How is the Minimal Residual Disease Testing Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the minimal residual disease testing market right now?
In recent years, the market size for minimal residual disease testing has experienced significant growth. It is projected that the market will expand from $1.59 billion in 2024 to $1.81 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%. This growth during the historic period can be attributed to factors such as progress in cancer research, the need for treatment monitoring, clinical proof, regulatory assistance, and improvement in patient outcomes.
How fast Is the minimal residual disease testing market expected to grow, and what’s its future value?
The market size for minimal residual disease testing is anticipated to significantly expand in the coming years. It’s projected to reach $2.96 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this projected growth during the forecast period include rising cancer rates, advancements in therapy, the trend towards precision medicine, a shift towards timely detection, and the integration of healthcare systems. Key trends expected during the forecast period include the incorporation of liquid biopsy methodologies, emphasis on early detection of recurrence, the increasing use of MRD testing in clinical trials, growing acceptance in pediatric oncology, and partnerships for research and development.
Get your minimal residual disease testing market report here!
What are the leading drivers of growth in the minimal residual disease testing market?
The growing occurrence of cancer is anticipated to fuel the escalation of the minimal residual disease testing market. Cancer is defined as an ailment when some of the body’s cells begin to develop uncontrollably and migrate to other areas within the body. Minimal residual disease testing, an extremely sensitive method for detecting cancer cells in the body, is typically used to determine cancer stages. This assists cancer patients in thwarting the ailment in its early stages, thereby stimulating the minimal residual disease testing market. For example, the American Cancer Society Inc., a US-based nonprofit organization, has reported that around 1.9 million new cancer cases are anticipated in 2022, potentially resulting in around 609,360 cancer-related deaths in the United States in 2022. Thus, the escalating occurrence of cancer is steering the growth of the minimal residual disease testing market.
What are the key segments defining the minimal residual disease testing market?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Who are the key players steering the development of the minimal residual disease testing market?
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
What emerging trends are influencing the growth of the minimal residual disease testing market?
The increasing popularity of product innovations is a key trend in the minimal residual disease testing market. To maintain their market position, major companies in this field are introducing new products. For example, Twist Bioscience, a US-based company specializing in synthetic biology and genomics, initiated the Twist MRD Panel in 2022 to further research and development in detecting minimal residual disease (MRD) during cancer screening. The Twist MRD Panel, a versatile and adaptable panel of genes tailored to detect an extremely low concentration of remaining cancer cells in a patient’s blood, can be incorporated into a standard next-generation sequencing (NGS) procedure, effectively identifying any MRD within a five-day timeframe.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9970
Which regions are most influential in expanding the minimal residual disease testing market?
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Analytical Standards Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/analytical-standards-global-market-report
Healthcare Analytical Testing Services Global Market Report 2024
Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
